Quantum Genomics Société Anonyme Management
Management criteria checks 1/4
Quantum Genomics Société Anonyme's CEO is Jean-Philippe Milon, appointed in Apr 2018, has a tenure of 5.92 years. directly owns 2.17% of the company’s shares, worth €77.21K. The average tenure of the management team and the board of directors is 5 years and 2.2 years respectively.
Key information
Jean-Philippe Milon
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.9yrs |
| CEO ownership | 2.2% |
| Management average tenure | 5yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -€18m |
| Mar 31 2023 | n/a | n/a | -€22m |
| Dec 31 2022 | n/a | n/a | -€25m |
| Sep 30 2022 | n/a | n/a | -€21m |
| Jun 30 2022 | n/a | n/a | -€20m |
| Mar 31 2022 | n/a | n/a | -€19m |
| Dec 31 2021 | €1m | €246k | -€17m |
| Sep 30 2021 | n/a | n/a | -€18m |
| Jun 30 2021 | n/a | n/a | -€18m |
| Mar 31 2021 | n/a | n/a | -€17m |
| Dec 31 2020 | €863k | €240k | -€16m |
| Sep 30 2020 | n/a | n/a | -€14m |
| Jun 30 2020 | n/a | n/a | -€10m |
| Mar 31 2020 | n/a | n/a | -€10m |
| Dec 31 2019 | €378k | €236k | -€10m |
Compensation vs Market: Insufficient data to establish whether Jean-Philippe's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Jean-Philippe's compensation has increased whilst the company is unprofitable.
CEO
Jean-Philippe Milon (63 yo)
5.9yrs
Tenure
€1,433,077
Compensation
Dr. Jean-Philippe Milon, PhD., has been the Chief Executive Officer at Quantum Genomics Société Anonyme since April 06, 2018, and serves as its MD, and has also been its Director since June 17, 2019. Dr. M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Chairman | 5.9yrs | €1.43m | 2.17% € 77.2k | |
| Administrative & Financial Director | 4.2yrs | no data | no data | |
| Chief Medical Officer | 6.9yrs | no data | no data | |
| Head of Regulatory Affairs | 1.8yrs | no data | no data |
5.0yrs
Average Tenure
Experienced Management: 2QG's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Chairman | 4.8yrs | €1.43m | 2.17% € 77.2k | |
| Member of Scientific & Clinical Advisory Board | 1.8yrs | no data | no data | |
| Director | no data | €295.81k | 2.01% € 71.4k | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 8.1yrs | no data | no data | |
| Independent Director | 2.2yrs | no data | no data | |
| Director | 6.2yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 1.8yrs | no data | no data | |
| Director | 2.2yrs | no data | no data |
2.2yrs
Average Tenure
60.5yo
Average Age
Experienced Board: 2QG's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/09 11:50 |
| End of Day Share Price | 2023/12/11 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quantum Genomics Société Anonyme is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Stephanie Lefebvre | Gilbert Dupont |
| Martial Descoutures | Invest Securities |